An interventional study of high incentive and low incentive in Stroke, sponsored by Cereneo AG. Terminated at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-13.
Sponsored by Cereneo AG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 216 studies in Stroke with a site in Switzerland, this one is the 99th largest by enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2015, is one of 95 with no phase, and was the 63rd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18–85
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 69 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 216 have an industry lead sponsor. The 10 most frequent:
Cereneo AG is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Cereneo AG has 6 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 216 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the use of motivating/rewarding features in a computer based arm rehabilitation program. Half of the subjects will take part, besides receiving standard therapy, in a computer based program delivering a game like scenario with visual effects and monetary rewards in case of successful level completion, while the other half will take part in a similar program without visual effects or the possibility to earn money.
Rewards not only increase motivation to train, but have also been shown to influence motor skill learning via activation of dopaminergic brain structures. In goal oriented tasks, receiving information about goal achievement has a rewarding value, which is further increased if performance has monetary consequences. Computer games often strengthen this kind of information by presenting explosions and other salient stimuli when a goal is achieved (e.g. a target has been reached). The current study investigates the outcome of an arm rehabilitation program, based on such a computer game delivered in two versions. Stroke patients are asked to use their impaired arms to perform goal oriented movements. Movements are translated into movements of a virtual arm on a computer screen. Goals are "meteors", threatening to destroy a planet on which they fall, if not caught by the virtual arm. One version of the computer game delivers state of the art graphics including a number of visual effects and, if the planet was protected successfully, information about a monetary reward, whereas the other version of the program delivers schematic graphic objects only. Training time and intensity are kept constant and outcome measures, including standard clinical motor assessments, are compared between the groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
game version including visual effects and monetary rewards
Behavioral: high incentive
game version without visual effects or monetary rewards
Behavioral: low incentive
Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
Subjects are required to use their arms in order to control a virtual "hand" on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards.
Change in ArmeoSenso - hand workspace
The subject moves the affected arm as far as possible in all directions while sitting in a gaming position. Movement range is recorded.
Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22): Main outcome is the change in hand workspace over the training intervention.
Motivation questionnaire
Measures motivation to train.
Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22)
Wolf Motor Function Test
Quantifies upper extremity motor ability through timed and functional tasks.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
Fugl-Meyer Assessment Upper Extremity
Measures motor impairment.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
Box and Blocks Test
Measures gross manual dexterity.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
ArmeoSenso: pointing task
Goal is to reach targets in the transversal plane in front of the subject: number of targets and time.
Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22)
Motor Activity Log 14 (MAL-14)
Self-reported movement ability.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
Barthel Index
Measure of independence in daily living.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
NIHSS
Measure of stroke severity.
Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)
Ran from Jan 2015 to primary completion in Oct 2019, 57 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cereneo AG